search
Back to results

The Effect of Vitamin D Supplementation on Cardiovascular Risk Factors (D-COR)

Primary Purpose

Vitamin D Deficiency

Status
Completed
Phase
Phase 3
Locations
Norway
Study Type
Interventional
Intervention
Cholecalciferol
Placebo
Sponsored by
University of Tromso
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Vitamin D Deficiency focused on measuring vitamin D, blood pressure, serum lipids, glucose metabolism, muscle function, arterial stiffness, depression, psoriasis, sleep, bone density

Eligibility Criteria

20 Years - 80 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • participated in The 7th survey in The Tromsø study
  • vitamin D deficiency

Exclusion Criteria:

  • primary hyperparathyroidism
  • granulomatous disease
  • reduced kidney function
  • systolic blood pressure > 174 mmHg
  • diastolic blood pressure > 104 mmHg
  • diabetes
  • renal stones last 5 years
  • use of solarium on regular basis
  • planned holidays in tropical areas
  • clinical depression
  • clinical signs of vitamin D deficiency (muscle weakness)
  • use of vitamin D supplements
  • serious illness

Sites / Locations

  • University Hospital of North Norway

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

cholecalciferol

placebo

Arm Description

vitamin D (as a 20 000 IU capsule) will be given once a week for 4 months

placebo capsules (identical looking to the vitamin D capsules) will be given once a week for 4 months

Outcomes

Primary Outcome Measures

Change from baseline in systolic and diastolic blood pressure

Secondary Outcome Measures

Change from baseline in hand-grip, quadriceps and biceps muscle strength measured by hand held dynamometry .
Change from baseline in score on Becks Depression Inventory
Change from baseline in cognitive function evaluated with The Twelve Word Memory Test
Change from baseline in cognitive function evaluated with The Digit Symbol Coding Test
Change from baseline in cognitive function evaluated with The Tapping Test
Change from baseline in arterial stiffness and endothelial function evaluated with pulse wave velocity
Change from baseline in arterial stiffness and endothelial function evaluated with augmentation index (AIX)
Change from baseline in arterial stiffness and endothelial function evaluated with the subendocardial viability ratio (SEVR)
Change from baseline in number of subjects with nasal staphylococcus aureus colonization
Change from baseline in bone mass density measured with dual energy x-ray absorptiometry (DEXA) at the lumbar spine and hip
Change from baseline in the bone turnover marker serum type 1 procollagen (P1NP)
Change from baseline in the bone turnover marker serum collagen type 1 cross-linked C-telopeptide (CTX-1)
Change from baseline in serum marker of interferon-γ mediated macrophage activation
Change from baseline in serum vitamin B6 status.
Change from baseline in the glycosylation marker HbA1c
Change from baseline in the glycosylation marker the receptor for advanced glycosylation end products (s-RAGE)
Change from baseline in the glycosylation marker carboxy-methyllysine
Change from baseline in psoriasis Activity in subjects with psoriasis evaluated with the Self-Administered Psoriasis Area Severity Index (SAPASI)
Change from baseline in psoriasis Activity in subjects with psoriasis, evaluated with the Dermatological Life Quality Index (DLQI)
Change from baseline in psoriasis Activity in subjects with psoriasis, evaluated with the Psoriasis Area Severity Index (PASI)
Change from baseline in transcriptomic profile (mRNA) in adipose tissue biopsies
Change from baseline in number of subjects with nocturnal legg cramps
Change from baseline in sleep pattern evaluated with the Tromsø Study 7th Survey sleep pattern questionnaire
Change from baseline in the serum total cholesterol
Change from baseline in the serum HDL-cholesterol
Change from baseline in the serum LDL-cholesterol
Change from baseline in the serum triglycerides
Change from baseline in the serum Apolipoprotein A1
Change from baseline in the serum Apolipoprotein B,
Change from baseline in insulin resistance evaluated with the homeostasis model assessment (HOMA) index based on fasting serum glucose and serum insulin
Change from baseline in proteomic profile with relative quantification in adipose tissue biopsies with the use of Liquid chromatography mass spectrometry Technology (LC-MS/MS)
Change from baseline in metabolomic profile with relative quantification in adipose tissue biopsies with the use of Liquid chromatography mass spectrometry Technology (LC-MS/MS)

Full Information

First Posted
April 12, 2016
Last Updated
October 24, 2017
Sponsor
University of Tromso
search

1. Study Identification

Unique Protocol Identification Number
NCT02750293
Brief Title
The Effect of Vitamin D Supplementation on Cardiovascular Risk Factors
Acronym
D-COR
Official Title
The Effect of Vitamin D Supplementation on Cardiovascular Risk Factors in Subjects With Low Serum 25-hydroxyvitamin D Levels
Study Type
Interventional

2. Study Status

Record Verification Date
October 2017
Overall Recruitment Status
Completed
Study Start Date
June 2015 (Actual)
Primary Completion Date
August 2017 (Actual)
Study Completion Date
September 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Tromso

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Six-hundred subjects with vitamin D deficiency will be randomized to vitamin D 3000 IU per day versus placebo for 4 months, with effects on cardiovascular risk factors as main endpoint
Detailed Description
Vitamin D is a hormone with effects not only on the skeleton, but on most tissues in the body. Lack of vitamin D is associated with cardio-vascular disease (CVD) and type 2 diabetes, and also with risk factors for these diseases like hypertension, dyslipidemia, insulin resistance, and endothelial dysfunction. However, intervention studies with vitamin D have been inconclusive regarding diseases and risk factors. Most of these studies were done in white, Western populations in subjects fairly vitamin D sufficient, and accordingly, no benefits were to be expected. Also, in many studies the doses of vitamin D have been too low, and the studies underpowered. To firmly establish the role of vitamin D regarding CVD risk factors we will in the present study include 600 subjects with vitamin D deficiency (serum 25-hydroxyvitamin D (25(OH)D) < 30 nmol/L) and randomize to high dose vitamin D (3000 IU per day) versus placebo for four months. The subjects will be recruited based on 25(OH)D measurements in the forthcoming 7th survey in the Tromsø study where more than 20 000 subjects are expected to attend. If our hypotheses are correct and the vitamin D supplement has a positive effect, this will be of great importance not only in countries with low sun exposure, but particularly for subjects in developing countries where vitamin D deficiency is highly prevalent.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Vitamin D Deficiency
Keywords
vitamin D, blood pressure, serum lipids, glucose metabolism, muscle function, arterial stiffness, depression, psoriasis, sleep, bone density

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
411 (Actual)

8. Arms, Groups, and Interventions

Arm Title
cholecalciferol
Arm Type
Active Comparator
Arm Description
vitamin D (as a 20 000 IU capsule) will be given once a week for 4 months
Arm Title
placebo
Arm Type
Placebo Comparator
Arm Description
placebo capsules (identical looking to the vitamin D capsules) will be given once a week for 4 months
Intervention Type
Drug
Intervention Name(s)
Cholecalciferol
Other Intervention Name(s)
Dekristol
Intervention Description
Vitamin D preparation
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
placebo
Primary Outcome Measure Information:
Title
Change from baseline in systolic and diastolic blood pressure
Time Frame
4 months
Secondary Outcome Measure Information:
Title
Change from baseline in hand-grip, quadriceps and biceps muscle strength measured by hand held dynamometry .
Time Frame
4 months
Title
Change from baseline in score on Becks Depression Inventory
Time Frame
4 months
Title
Change from baseline in cognitive function evaluated with The Twelve Word Memory Test
Time Frame
4 months
Title
Change from baseline in cognitive function evaluated with The Digit Symbol Coding Test
Time Frame
4 months
Title
Change from baseline in cognitive function evaluated with The Tapping Test
Time Frame
4 months
Title
Change from baseline in arterial stiffness and endothelial function evaluated with pulse wave velocity
Time Frame
4 months
Title
Change from baseline in arterial stiffness and endothelial function evaluated with augmentation index (AIX)
Time Frame
4 months
Title
Change from baseline in arterial stiffness and endothelial function evaluated with the subendocardial viability ratio (SEVR)
Time Frame
4 months
Title
Change from baseline in number of subjects with nasal staphylococcus aureus colonization
Time Frame
4 months
Title
Change from baseline in bone mass density measured with dual energy x-ray absorptiometry (DEXA) at the lumbar spine and hip
Time Frame
4 months
Title
Change from baseline in the bone turnover marker serum type 1 procollagen (P1NP)
Time Frame
4 months
Title
Change from baseline in the bone turnover marker serum collagen type 1 cross-linked C-telopeptide (CTX-1)
Time Frame
4 months
Title
Change from baseline in serum marker of interferon-γ mediated macrophage activation
Time Frame
4 months
Title
Change from baseline in serum vitamin B6 status.
Time Frame
4 months
Title
Change from baseline in the glycosylation marker HbA1c
Time Frame
4 months
Title
Change from baseline in the glycosylation marker the receptor for advanced glycosylation end products (s-RAGE)
Time Frame
4 months
Title
Change from baseline in the glycosylation marker carboxy-methyllysine
Time Frame
4 months
Title
Change from baseline in psoriasis Activity in subjects with psoriasis evaluated with the Self-Administered Psoriasis Area Severity Index (SAPASI)
Time Frame
4 months
Title
Change from baseline in psoriasis Activity in subjects with psoriasis, evaluated with the Dermatological Life Quality Index (DLQI)
Time Frame
4 months
Title
Change from baseline in psoriasis Activity in subjects with psoriasis, evaluated with the Psoriasis Area Severity Index (PASI)
Time Frame
4 months
Title
Change from baseline in transcriptomic profile (mRNA) in adipose tissue biopsies
Time Frame
4 months
Title
Change from baseline in number of subjects with nocturnal legg cramps
Time Frame
4 months
Title
Change from baseline in sleep pattern evaluated with the Tromsø Study 7th Survey sleep pattern questionnaire
Time Frame
4 months
Title
Change from baseline in the serum total cholesterol
Time Frame
4 months
Title
Change from baseline in the serum HDL-cholesterol
Time Frame
4 months
Title
Change from baseline in the serum LDL-cholesterol
Time Frame
4 months
Title
Change from baseline in the serum triglycerides
Time Frame
4 months
Title
Change from baseline in the serum Apolipoprotein A1
Time Frame
4 months
Title
Change from baseline in the serum Apolipoprotein B,
Time Frame
4 months
Title
Change from baseline in insulin resistance evaluated with the homeostasis model assessment (HOMA) index based on fasting serum glucose and serum insulin
Time Frame
4 months
Title
Change from baseline in proteomic profile with relative quantification in adipose tissue biopsies with the use of Liquid chromatography mass spectrometry Technology (LC-MS/MS)
Time Frame
4 months
Title
Change from baseline in metabolomic profile with relative quantification in adipose tissue biopsies with the use of Liquid chromatography mass spectrometry Technology (LC-MS/MS)
Time Frame
4 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: participated in The 7th survey in The Tromsø study vitamin D deficiency Exclusion Criteria: primary hyperparathyroidism granulomatous disease reduced kidney function systolic blood pressure > 174 mmHg diastolic blood pressure > 104 mmHg diabetes renal stones last 5 years use of solarium on regular basis planned holidays in tropical areas clinical depression clinical signs of vitamin D deficiency (muscle weakness) use of vitamin D supplements serious illness
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
rolf Jorde, Professor
Organizational Affiliation
University of Tromso
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospital of North Norway
City
Tromsø
ZIP/Postal Code
9038
Country
Norway

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
not planned
Citations:
PubMed Identifier
30472553
Citation
Jorde R, Kubiak J, Svartberg J, Fuskevag OM, Figenschau Y, Martinaityte I, Grimnes G. Vitamin D supplementation has no effect on cognitive performance after four months in mid-aged and older subjects. J Neurol Sci. 2019 Jan 15;396:165-171. doi: 10.1016/j.jns.2018.11.020. Epub 2018 Nov 17.
Results Reference
derived

Learn more about this trial

The Effect of Vitamin D Supplementation on Cardiovascular Risk Factors

We'll reach out to this number within 24 hrs